Dalfampridine and Clostridium difficile colitis - a phase IV clinical study of FDA data

Summary:

Clostridium difficile colitis is found among people who take Dalfampridine, especially for people who are male, 30-39 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Dalfampridine and have Clostridium difficile colitis. It is created by eHealthMe based on reports of 4,490 people who have side effects when taking Dalfampridine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Jun, 30, 2022

4,490 people reported to have side effects when taking Dalfampridine.
Among them, 15 people (0.33%) have Clostridium difficile colitis.


What is Dalfampridine?

Dalfampridine has active ingredients of dalfampridine. eHealthMe is studying from 4,496 Dalfampridine users for its effectiveness, alternative drugs and more.

What is Clostridium difficile colitis?

Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection) is found to be associated with 1,908 drugs and 1,584 conditions by eHealthMe.

Number of Dalfampridine and Clostridium difficile colitis reports submitted per year:

Could Dalfampridine cause Clostridium difficile colitis?

Time on Dalfampridine when people have Clostridium difficile colitis *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Clostridium difficile colitis when taking Dalfampridine *:

  • female: 46.67 %
  • male: 53.33 %

Age of people who have Clostridium difficile colitis when taking Dalfampridine *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 57.14 %
  • 40-49: 28.57 %
  • 50-59: 7.14 %
  • 60+: 7.14 %

Common drugs people take besides Dalfampridine *:

  1. Zanaflex: 8 people, 53.33%
  2. Tysabri: 8 people, 53.33%
  3. Provigil: 8 people, 53.33%
  4. Lexapro: 8 people, 53.33%
  5. Lamisil: 8 people, 53.33%
  6. Flomax: 8 people, 53.33%
  7. Clonazepam: 8 people, 53.33%
  8. Ambien: 8 people, 53.33%
  9. Vitamin D3: 5 people, 33.33%
  10. Probiotic: 1 person, 6.67%

Common side effects people have besides Clostridium difficile colitis *:

  1. Progressive Multifocal Leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells): 8 people, 53.33%
  2. Pneumonia: 8 people, 53.33%
  3. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 8 people, 53.33%
  4. Candidiasis (candidiasis or thrush is a fungal infection): 8 people, 53.33%
  5. Nausea (feeling of having an urge to vomit): 4 people, 26.67%
  6. Nausea And Vomiting: 3 people, 20.00%
  7. Diarrhea: 3 people, 20.00%
  8. Abdominal Pain: 3 people, 20.00%
  9. Sepsis (a severe blood infection that can lead to organ failure and death): 2 people, 13.33%
  10. Gastritis (inflammation of stomach): 1 person, 6.67%

Common conditions people have *:

  1. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 10 people, 66.67%
  2. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 13.33%
  3. Gait Disturbance: 2 people, 13.33%
  4. Progressive Multiple Sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord): 1 person, 6.67%
  5. Muscle Spasms (muscle contraction): 1 person, 6.67%
  6. Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 6.67%
  7. Back Pain: 1 person, 6.67%
  8. Abdominal Pain Upper: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Dalfampridine and have Clostridium difficile colitis?

Check whether Clostridium difficile colitis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Clostridium difficile colitis and when was it recovered:

Expand to all the drugs that have ingredients of dalfampridine:

Alternative drugs to, pros and cons of Dalfampridine:

Common Dalfampridine side effects:

Browse all side effects of Dalfampridine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Clostridium difficile colitis treatments and more:

COVID vaccines that are related to Clostridium difficile colitis:

Common drugs associated with Clostridium difficile colitis:

All the drugs that are associated with Clostridium difficile colitis:

Common conditions associated with Clostridium difficile colitis:

All the conditions that are associated with Clostridium difficile colitis:

How the study uses the data?

The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Dalfampridine) and Dalfampridine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: